Please login to the form below

Not currently logged in
Email:
Password:

Santarus begins Zegerid litigation against Par

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

The University of Missouri, which is licensor of the patents, has joined Santarus in the litigation as a co-plaintiff.

The lawsuit refers to an Abbreviated New Drug Application (ANDA) filed by Par with the FDA to market a generic version of Zegerid Capsules before the 2016 expiration of three listed US patents (6,645,988, 6,489,346 and 6,699,885).

Santarus filed the lawsuit within the 45 days limit required to prevent the FDA from approving París ANDA for 30 months, or until a district court decision ruling against Santarus.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...